Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Total Debt
Short-term and long-term borrowings combined.
Entera Bio Ltd.NASDAQ: ENTX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 103.6% from a year ago
Total debt stood at $448K at the end of Q1 FY2026, up 103.6% from a year earlier and down 8.6% from the prior quarter. Over 3 fiscal years it compounded at +75.3% a year.
Context
- Total debt amounted to 3.4% of total assets at the end of Q1 FY2026, up 2.4 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +103.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 490K USD
- Year-over-year change
- +80.1%
- 4-year CAGR
- +12.9%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 490K | +80.1% |
| FY2024 | 2024-12-31 | 272K | -30.3% |
| FY2023 | 2023-12-31 | 390K | +328.6% |
| FY2022 | 2022-12-31 | 91K | -69.9% |
| FY2021 | 2021-12-31 | 302K | — |
Total Debt vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 total debt of $448K is the 9th highest of the 10 companies compared; the peer median is $23.03M.
- Its year-over-year change of +103.6% is the 3rd highest of 9, against a peer median of -9.7%.
- Total debt amounts to 3.4% of total assets for ENTX, versus a peer median of 17.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $304.46M | +230.8% | +62.2% | 163.3% | |
| Mar 2026 | $80.5M | -10.1% | -20.1% | 68.4% | |
| Mar 2026 | $31.16M | +7.5% | +568.1% | 23.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $25.93M | — | — | 38.8% |
| Mar 2026 | $23.03M | -9.4% | -7.5% | 8.5% | |
| Mar 2026 | $8.7M | -22.9% | -33.7% | 17.5% | |
| Mar 2026 | $2.47M | -37.5% | -24.2% | 4.2% | |
| Mar 2026 | $456.93K | +177.6% | +71.7% | 1.5% | |
| Mar 2026 | $448K | +103.6% | +75.3% | 3.4% | |
| Apr 2026 | $184K | -16.7% | -2.6% | 1.2% | |
| Peer median (excluding ENTX) | $23.03M | -9.7% | -5.1% | 17.5% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.